InvestorsHub Logo
Followers 6
Posts 217
Boards Moderated 0
Alias Born 05/19/2004

Re: DeepDive post# 924

Sunday, 05/20/2018 11:33:38 PM

Sunday, May 20, 2018 11:33:38 PM

Post# of 1462
We agree that Cox is all science, and not a good investment advisor. We also must agree that he's been a long time proponent of BTX.

Anyway, I just reread his article and went through the 20 slides again. Notice the first 8 slides are background also mentioning Opregen and AST. Slide 9 presents the AgeX pipeline including Renelon. And then COX7A1 is highlighted on slides 16-19 and the Summary ends with 3 AgeX focus activities...the last of which is "Therapy designed to induce scarless tissue regeneration."

Six of the last 12 slides deal with "scarless healing." If you're making a strong presentation, don't you highlight your most exciting feature throughout and at the end?

If Cox is right that an artificial intelligence algorithm enabled them to already have found an FDA approved drug that can manipulate COX7A1, and the only delay is to get the patents and other safeguards in place to protect this research from competitors...then the 510(K) route could be ready anytime. Why would they be hyping it (indirectly) if it was 5 years away?

And presumably, as Cox indicates, once the device approval is received, they have a myriad of markets to try out...ranging from scars on damaged hearts to scars on cosmetic surgery!!!

I've seen these device approvals sneak into the market before and if they start showing results, the stock price can explode.

Must take a deep breath now, and let the positive AND negative possibilities percolate for a while. I wish we had a date for the AgeX separation from BTX.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent LCTX News